BEFORE YOU BEGIN
What to know.
- Ask for the exact finished product and its current approval record.
- A historical compounding committee discussion is not a drug approval.
- Claims about fertility or superiority need evidence for the proposed use.
A clearer path through the details.
Use this reading map to jump to the questions covered below.
Read the historical record accurately
In its 2022 compounding advisory materials, FDA discussed enclomiphene citrate as a substance that was not a component of an FDA-approved drug. The materials concerned potential compounding-list inclusion; they were not an approval announcement.
That document is a dated record, not a substitute for checking current product status. Ask a prescriber making an approval claim to identify the finished product and the relevant current FDA record.
Sources: FDA 2022 Pharmacy Compounding Advisory Committee summary · Resources for information on approved drugs
Do not confuse compounding with off-label use
FDA explains that compounded medicines are not FDA approved and are not reviewed before marketing for safety, effectiveness, and quality in the same way as approved drugs.
Off-label use describes an unapproved use of an approved medicine. Calling a product 'off label' does not by itself establish that the product is approved. Ask which of these situations actually applies to what you are being offered.
Sources: Understanding the risks of compounded drugs · Understanding unapproved use of approved drugs (off label)
Ask what evidence answers your question
Ask to see evidence for the specific goal being discussed: a hormone measurement, a symptom outcome, or a fertility outcome. Those are different questions. A claim that a medicine is 'cleaner' or 'better' is not enough to compare its benefits and risks.
Request an explanation of the uncertainty, alternatives, side effects to watch for, and follow-up. This article does not recommend enclomiphene, determine legal eligibility for compounding, or identify it as an interchangeable alternative to another prescription.
Sources: FDA 2022 Pharmacy Compounding Advisory Committee summary · Understanding unapproved use of approved drugs (off label)
TAKE TO YOUR APPOINTMENT
Questions to ask.
- What exact product would be supplied, and what is its current regulatory status?
- Which study supports the outcome we are discussing?
- Is this an approved product, a compounded product, or something else?
- What alternatives and uncertainties should I understand?
FOLLOW THE EVIDENCE
Sources & further reading
- FDA 2022 Pharmacy Compounding Advisory Committee summaryU.S. Food and Drug Administration · Accessed October 3, 2026
- Resources for information on approved drugsU.S. Food and Drug Administration · Accessed October 3, 2026
- Understanding the risks of compounded drugsU.S. Food and Drug Administration · Accessed October 3, 2026
- Understanding unapproved use of approved drugs (off label)U.S. Food and Drug Administration · Accessed October 3, 2026
EXPLORING CLINICAL CARE?
A separate next step.
Reform's separate website may help readers explore clinical care information. This link is not a claim that enclomiphene is available, approved, or suitable through that service; ask the prescribing team about the exact product and evidence.
Explore testosterone evaluation at Reform HRTPrime Health directs interested readers to Reform. This care-service link is separate from our clinical sources. About this relationship.
